Tectonic Therapeutic 3Q 2026: EPS ($1.08) — 10-Q Summary

Tectonic Therapeutic’s net loss widened year over year in the third quarter as operating expenses increased, led by higher platform development and unallocated costs and general and administrative expenses. Lower TX2100 and TX45 program costs partly offset the increases.Financial Highlights² Report…